Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Alumis Inc. Common StockNASDAQ: ALMS
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization remains negative
Q2 FY2026 depreciation & amortization was $0, compared with $870K a year earlier. Trailing-twelve-month depreciation & amortization was $2.65M. Over 3 fiscal years it compounded at +140.9% a year.
Context
- Depreciation & amortization amounted to 14.5% of revenue in FY2025.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $663.5K.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 3.5M USD
- Year-over-year change
- +10.9%
- 3-year CAGR
- +140.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.5M | +10.9% |
| FY2024 | 2024-12-31 | 3.15M | +145.5% |
| FY2023 | 2023-12-31 | 1.28M | +413.6% |
| FY2022 | 2022-12-31 | 250K | — |
Depreciation & Amortization vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -20.7% is the lowest of 10, against a peer median of +3.1%.
- Depreciation & amortization amounts to 35.9% of revenue for ALMS, versus a peer median of 6.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $2.65M USD | -20.7% | +140.9% | 35.9% |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $2.64M USD | +6.6% | +30.9% | — |
| LTM Mar 2026 | $2.43M USD | +1.2% | +1.2% | 1.0% | |
| LTM Mar 2026 | $2.41M USD | -1.0% | +34.3% | 0.8% | |
| LTM Mar 2026 | $528K USD | +7.3% | -17.1% | 6.3% | |
| LTM Mar 2026 | €392.86K EUR | -17.3% | -11.1% | 1339.4% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | €311K EUR | +214.1% | — | — |
| LTM Mar 2026 | $257.68K USD | +3.1% | -0.9% | — | |
| FY2025 | $234K USD | +88.7% | +55.1% | — | |
| LTM Mar 2026 | $226K USD | -16.3% | +27.5% | 383.1% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | +3.1% | +14.4% | 6.3% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 24.05M |
| Cost of Revenue | 250K | 0 | 3.15M | 3.5M |
| Gross Profit | (250K) | 0 | (3.15M) | 20.55M |
| Gross Margin | — | — | — | 85.5% |
| Research & Development | 101.05M | 137.68M | 265.55M | 386M |
| Selling, General & Admin | 12.55M | 20.5M | 35.2M | 91.86M |
| Operating Expenses | 113.6M | 158.17M | 297.6M | 447.76M |
| Depreciation & Amortization | 250K | 1.28M | 3.15M | 3.5M |
| EBITDA | (111.68M) | (153.71M) | (291.08M) | (248.39M) |
| EBITDA Margin | — | — | — | -1032.8% |
| Operating Income | (113.85M) | (158.17M) | (300.75M) | (427.2M) |
| Operating Margin | — | — | — | -1776.3% |
| Interest Income | 1.99M | 3.37M | 12.02M | 14.18M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.92M | 3.18M | 6.52M | 175.32M |
| Income Before Tax | (111.93M) | (154.99M) | (294.23M) | (251.89M) |
| Pre-Tax Margin | — | — | — | -1047.3% |
| Income Tax Expense | 0 | 0 | 0 | (8.56M) |
| Net Income | (111.93M) | (154.99M) | (294.23M) | (243.33M) |
| Net Margin | — | — | — | -1011.7% |
| EPS (Basic) | (14.93) | (2.99) | (10.38) | (2.32) |
| EPS (Diluted) | (14.93) | (2.99) | (10.38) | (2.32) |
| Weighted Avg Shares | 7.5M | 51.84M | 28.34M | 850.3M |
| Weighted Avg Shares (Diluted) | 7.5M | 51.84M | 28.34M | 850.3M |
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.